Skip to main content
Erschienen in:

11.10.2021 | Brief Report

Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study

verfasst von: Piero Ruscitti, Ilenia Di Cola, Onorina Berardicurti, Alessandro Conforti, Daniela Iacono, Ilenia Pantano, Gelsomina Rozza, Silvia Rossi, Ludovico De Stefano, Silvia Balduzzi, Antonio Vitale, Francesco Caso, Luisa Costa, Marcella Prete, Luca Navarini, Fabiola Atzeni, Giuliana Guggino, Federico Perosa, Luca Cantarini, Bruno Frediani, Carlomaurizio Montecucco, Francesco Ciccia, Roberto Giacomelli, Paola Cipriani

Erschienen in: Clinical Rheumatology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

The objective of this study is to describe the possible prognostic impact of smoking habit on adult-onset Still’s disease (AOSD) patients, by the assessment of clinical characteristics, life-threatening complications occurrence, and mortality in smokers than non-smokers. A multicentre retrospective study of prospectively followed-up AOSD patients included in Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort was conducted. Out of 185 AOSD assessed patients, 45 smokers were identified. These showed a higher frequency of pericarditis (35.5% vs 16.4%, p = 0.011), pleuritis (33.3% vs 14.3%, p = 0.008), and abdominal pain (17.7% vs 6.4%, p = 0.035). Furthermore, smokers showed higher values of systemic score (6.4 ± 2.2 vs 5.4 ± 1.8, p = 0.004), an increased rate of macrophage activation syndrome (MAS) (28.9% vs 6.4%, p < 0.0001) and of parenchymal lung disease (17.7% vs 12.6%, p = 0.035). Although not significant, these patients more frequently experienced a poor prognosis (13.3% vs 4.3%, p = 0.074). Smoking habit predicted MAS occurrence in both univariate (HR: 5.98, 95% CI: 2.45–14.57, p < 0.0001) and multivariate regression models (HR: 6.21, 95% CI: 2.46–15.70, p < 0.0001). Smokers had a significant higher risk of parenchymal lung disease in both univariate (HR: 3.97, 95% CI: 1.43–11.02, p = 0.008) and multivariate regression models (HR: 3.90, 95% CI: 1.36–11.23, p = 0.012). Smoking habit also increased the risk of mortality in univariate regression model (HR: 4.25, 95% CI: 1.33–13.55, p = 0.015). Smoking habit resulted to be a negative prognostic factor on AOSD patients. Smokers were characterised by a higher frequency of serositis and higher values of systemic score. Additionally, these patients were more frequently burdened by MAS and parenchymal lung disease associated with a poor prognosis.
Key points
Smoking habit resulted to be a negative prognostic factor on AOSD.
Smokers were characterised by an increased frequency of serositis and higher values of systemic score.
Cigarette exposure was associated with MAS and parenchymal lung disease in AOSD.
Literatur
3.
Zurück zum Zitat Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, Husami A, Watts A, Brunner HI, Huggins J, Mellins ED, Morgan EM, Ting T, Trapnell BC, Wikenheiser-Brokamp KA, Towe C, Grom AA (2019) Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol 71(11):1943–1954. https://doi.org/10.1002/art.41073CrossRefPubMedPubMedCentral Schulert GS, Yasin S, Carey B, Chalk C, Do T, Schapiro AH, Husami A, Watts A, Brunner HI, Huggins J, Mellins ED, Morgan EM, Ting T, Trapnell BC, Wikenheiser-Brokamp KA, Towe C, Grom AA (2019) Systemic juvenile idiopathic arthritis-associated lung disease: characterization and risk factors. Arthritis Rheumatol 71(11):1943–1954. https://​doi.​org/​10.​1002/​art.​41073CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Ruscitti P, Berardicurti O, Iacono D, Pantano I, Liakouli V, Caso F, Emmi G, Grembiale RD, Cantatore FP, Atzeni F, Perosa F, Scarpa R, Guggino G, Ciccia F, Barile A, Cipriani P, Giacomelli R (2020) Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Res Ther 22(1):151. https://doi.org/10.1186/s13075-020-02245-5CrossRefPubMedPubMedCentral Ruscitti P, Berardicurti O, Iacono D, Pantano I, Liakouli V, Caso F, Emmi G, Grembiale RD, Cantatore FP, Atzeni F, Perosa F, Scarpa R, Guggino G, Ciccia F, Barile A, Cipriani P, Giacomelli R (2020) Parenchymal lung disease in adult onset Still’s disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Res Ther 22(1):151. https://​doi.​org/​10.​1186/​s13075-020-02245-5CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Safy-Khan M, de Hair MJH, Welsing PMJ, van Laar JM, Jacobs JWG (2021) Society for Rheumatology research Utrecht (SRU). Current smoking negatively affects the response to methotrexate in RA in a dose-responsive way, independently of concomitant prednisone use. J Rheumatol 1:jrheum.200213. https://doi.org/10.3899/jrheum.200213 Safy-Khan M, de Hair MJH, Welsing PMJ, van Laar JM, Jacobs JWG (2021) Society for Rheumatology research Utrecht (SRU). Current smoking negatively affects the response to methotrexate in RA in a dose-responsive way, independently of concomitant prednisone use. J Rheumatol 1:jrheum.200213. https://​doi.​org/​10.​3899/​jrheum.​200213
13.
Zurück zum Zitat Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19(3):424–430PubMed Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T et al (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19(3):424–430PubMed
14.
Zurück zum Zitat Ruscitti P, Iacono D, Ciccia F, Emmi G, Cipriani P, Grembiale RD, Perosa F, Emmi L, Triolo G, Giacomelli R, Valentini G (2018) Macrophage activation syndrome in patients affected by adult-onset still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. J Rheumatol 45(6):864–872. https://doi.org/10.3899/jrheum.170955CrossRefPubMed Ruscitti P, Iacono D, Ciccia F, Emmi G, Cipriani P, Grembiale RD, Perosa F, Emmi L, Triolo G, Giacomelli R, Valentini G (2018) Macrophage activation syndrome in patients affected by adult-onset still disease: analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. J Rheumatol 45(6):864–872. https://​doi.​org/​10.​3899/​jrheum.​170955CrossRefPubMed
15.
16.
Zurück zum Zitat Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70(2):118–136CrossRef Pouchot J, Sampalis JS, Beaudet F, Carette S, Décary F, Salusinsky-Sternbach M, Hill RO, Gutkowski A, Harth M, Myhal D et al (1991) Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore) 70(2):118–136CrossRef
19.
Zurück zum Zitat Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, Ruppert A, Lødrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas DA, Silverman EK, Goldstein DB, Investigators ICGN (2009) A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 5(3):e1000421. https://doi.org/10.1371/journal.pgen.1000421CrossRefPubMedPubMedCentral Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, Need AC, Feng S, Hersh CP, Bakke P, Gulsvik A, Ruppert A, Lødrup Carlsen KC, Roses A, Anderson W, Rennard SI, Lomas DA, Silverman EK, Goldstein DB, Investigators ICGN (2009) A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet 5(3):e1000421. https://​doi.​org/​10.​1371/​journal.​pgen.​1000421CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Mehta M, Dhanjal DS, Paudel KR, Singh B, Gupta G, Rajeshkumar S, Thangavelu L, Tambuwala MM, Bakshi HA, Chellappan DK, Pandey P, Dureja H, Charbe NB, Singh SK, Shukla SD, Nammi S, Aljabali AA, Wich PR, Hansbro PM, Satija S, Dua K (2020) Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update. Inflammopharmacology 28(4):795–817. https://doi.org/10.1007/s10787-020-00698-3CrossRefPubMed Mehta M, Dhanjal DS, Paudel KR, Singh B, Gupta G, Rajeshkumar S, Thangavelu L, Tambuwala MM, Bakshi HA, Chellappan DK, Pandey P, Dureja H, Charbe NB, Singh SK, Shukla SD, Nammi S, Aljabali AA, Wich PR, Hansbro PM, Satija S, Dua K (2020) Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: an update. Inflammopharmacology 28(4):795–817. https://​doi.​org/​10.​1007/​s10787-020-00698-3CrossRefPubMed
23.
24.
Zurück zum Zitat Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, Berardicurti O, Guggino G, Di Benedetto P, Di Bartolomeo S, Valenti M, Triolo G, Giacomelli R (2017) Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev 16(1):16–21. https://doi.org/10.1016/j.autrev.2016.09.016CrossRefPubMed Ruscitti P, Cipriani P, Ciccia F, Masedu F, Liakouli V, Carubbi F, Berardicurti O, Guggino G, Di Benedetto P, Di Bartolomeo S, Valenti M, Triolo G, Giacomelli R (2017) Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. Autoimmun Rev 16(1):16–21. https://​doi.​org/​10.​1016/​j.​autrev.​2016.​09.​016CrossRefPubMed
25.
Zurück zum Zitat Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Caso F, Perosa F, Atzeni F, Cantatore FP, Scarpa R, Ciccia F, Giacomelli R (2020) Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort. Rheumatol Int 40(1):107–113. https://doi.org/10.1007/s00296-019-04358-wCrossRefPubMed Ruscitti P, Cipriani P, Liakouli V, Iacono D, Pantano I, Caso F, Perosa F, Atzeni F, Cantatore FP, Scarpa R, Ciccia F, Giacomelli R (2020) Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort. Rheumatol Int 40(1):107–113. https://​doi.​org/​10.​1007/​s00296-019-04358-wCrossRefPubMed
Metadaten
Titel
Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study
verfasst von
Piero Ruscitti
Ilenia Di Cola
Onorina Berardicurti
Alessandro Conforti
Daniela Iacono
Ilenia Pantano
Gelsomina Rozza
Silvia Rossi
Ludovico De Stefano
Silvia Balduzzi
Antonio Vitale
Francesco Caso
Luisa Costa
Marcella Prete
Luca Navarini
Fabiola Atzeni
Giuliana Guggino
Federico Perosa
Luca Cantarini
Bruno Frediani
Carlomaurizio Montecucco
Francesco Ciccia
Roberto Giacomelli
Paola Cipriani
Publikationsdatum
11.10.2021
Verlag
Springer International Publishing
Erschienen in
Clinical Rheumatology / Ausgabe 3/2022
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-021-05929-8

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

RA-Basistherapie: Neues zu altbekannten Medikamenten

Zu glauben, zur Basistherapie der rheumatoiden Arthritis (RA) mit Methotrexat und Glukokortikoiden sei bereits alles gesagt, hat sich beim diesjährigen Rheuma-Update-Seminar wieder einmal als falsch erwiesen. Sogar eine in der Praxis „viel geübte Strategie“ wurde hinterfragt.

Erhöhte Hypoglykämie-Gefahr nach Beginn einer Betablockertherapie

Beginnen Diabetiker eine Behandlung mit Betablockern, verdoppelt sich in den ersten Wochen fast das Hypoglykämie-Risiko, normalisiert sich mit der Zeit aber wieder. Besondere Vorsicht ist unter einer Therapie mit nichtselektiven Wirkstoffen geboten.

Nierenzellkarzinom: Daten zur Lebensqualität unter HIF-Inhibition vorgelegt

Seit wenigen Wochen ist mit Belzutifan eine neue Wirkstoffklasse beim fortgeschrittenen klarzelligen Nierenzellkarzinom in der EU zugelassen. Frisch publizierte Ergebnisse zur Lebensqualität erweitern jetzt die Datenbasis zur Risiko-Nutzen-Bewertung für den HIF-2α-Inhibitor.

Warum genderspezifische Medizin notwendig ist 

Laut Zahlen der WHO aus dem Jahr 2024 sterben zwei Frauen pro Minute an Krankheiten, die mit geschlechtsspezifischen Faktoren zusammenhängen. Außerdem wirken Medikamente bei ihnen oft anders als bei Männern. Zeit für ein genderspezifisches Denken in der Medizin.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.